Navigation Links
BioVex Closes Second Round of Series E Financing
Date:11/15/2007

Second and Final Close Completes $35 Million Financing

WOBURN, Mass., Nov. 15 /PRNewswire/ -- BioVex Inc, a clinical stage company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had completed its Series E financing, concurrent with the completion of a venture debt transaction, raising a total of $35m of funds.

BioVex intends to use the capital to complete its preparations for, and to commence, a Phase III study with its lead product OncoVex GM-CSF for the treatment of melanoma as well as to complete studies in head and neck cancer and pancreatic cancer. The financing will also fund the Company's second program, ImmunoVEX HSV2, a vaccine for genital herpes, through to Phase II.

The Series E placement was led by Triathlon Medical Ventures who were joined by new investors New Science Ventures and Harris and Harris Group, Inc., as well as existing investors. The venture debt facility was provided by Oxford Finance Corporation and Silicon Valley Bank.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX GM-CSF, is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX GM-CSF has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX GM-CSF as stand alone therapy in patients with un-resectab
'/>"/>

SOURCE BioVex Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... 2015 The Pittcon 2015 Exposition, ... Ernest N. Morial Convention Center in New Orleans, ... February 19, 2015) displaying products and services used ... government labs. The Exposition will offer the latest ... to, analytical chemistry; drug discovery; nanotechnology; life sciences ...
(Date:2/26/2015)... Albany, NY (PRWEB) February 26, 2015 ... Market Research “Agricultural Biotechnology Market For Transgenic Crops (Corn, ... – Global Industry Analysis, Size, Share, Growth, Trends and ... valued at USD 15,300 million in 2012 and is ... at a CAGR of 9.5% from 2013 to 2019. ...
Breaking Biology Technology:Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3
... experiments indicate that infants aged 4 months or ... to detect changes in the number of objects. However, ... This week in the online journal PLoS Biology, Vronique ... evidence showing that very young infants are sensitive to ...
... Boston Scientific,Corporation (NYSE: BSX ) today announced financial results ... as well as guidance for net,sales and earnings per share ... quarter highlights:, -- Achieved adjusted EPS of $0.24 and ... both exceeding most recently issued guidance -- Grew cardiac ...
... Feb. 4 Sangamo BioSciences,Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP,Therapeutic ... at 12:30 pm (ET) on Tuesday, February 12, 2008 ... City., The presentation will be webcast live and ...
Cached Biology Technology:Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 2Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 3Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 4Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 5Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 6Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 7Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 8Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 9Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 10Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 11Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 12Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 13Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 14Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 15Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 16Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 17Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 18Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 19Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 20Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 21Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 22Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 23Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 24Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 25Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 26Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 27Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 28Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007 29Sangamo BioSciences to Present at the BIO CEO & Investor Conference 2
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... for genetic diseases during in vitro fertilization offers couples ... genetic glitch could potentially cause doctors to misdiagnose a ... , Citing concerns about the accuracy of preimplantation ... the healthiest embryos during IVF, UF researchers set out ...
... a bid to facilitate collaboration among other biomolecular ... Laboratory has become the first institution outside the ... Consortium of Great Britain. , The BioSimGrid was ... Oxford, Southampton, Bristol, Birkbeck, Nottingham and York. Researchers ...
... lead is a well-known human health hazard, researchers at the ... of how it may work in mice to harm the ... bacteria, viruses and other bugs. , The discovery adds insight ... their emphasis from the immediate public health threat to understanding ...
Cached Biology News:Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3Grid bridges 4,800 miles for molecular repositories 2The dangerous legacy of lead 2